TransMedics Cancels IPO

TransMedics Inc., an Andover, Mass.-based developer of portable life support systems for organ transplants, has withdrawn its registration for an $86.25 million IPO, citing “market conditions.” It haad planned to trade on the Nasdaq under ticker symbol TMDX, with Morgan Stanley serving as lead underwriter.

The company has raised around $90 million in total VC funding since 2000, including a $25.5 million Series D round earlier this year. Shareholders include 3i Group (24.4% stake), Tudor Investment Corp. (14.7%), Flagship Ventures (14.3%), VantagePoint Venture Partners (10%), Sherbrooke Partners (9.2%), Alta Partners (8.9%), CB Health Ventures (7.4%), Posco BioVentures and Sagamore Bioventures.

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.